Mechanisms of action and modulation of fluorouracil

Seminars in Radiation Oncology

Volumn 7, Issue 4, 1997, Pages 249-259

  Grem, J L ^a  

^a Division of Clinical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOXIFLURIDINE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; OXONIC ACID; TEGAFUR; URACIL;

ANIMAL CELL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEPATIC ARTERY; HEPATOMA CELL; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IONIZING RADIATION; MAJOR CLINICAL STUDY; META ANALYSIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0030842931     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(97)80023-9     Document Type: Article

References (100)

1. Heidelberger C Chaudhuari NK Danenberg P Fluorinated pyrimidines: A new class of tumor, inhibitory compounds Nature 179 1957 663 666
2. Grem JL 5-Fluoropyrimidines Chabner BA Longo DL Cancer Chemotherapy and Biotherapy: Principles and Practice ed 2 1996 Lippincott Philadelphia, PA 149 211
3. Domin BA Mabony WB Zimmerman TP Transport of 5-fluorouracil and uracil into human erythrocytes Biochem Pharmacol 46 1993 503 510
4. Santi DV McHenry CS Raines RT Kinetics and thermodynamics of the interaction of 5-fluouro-2′-deoxy-uridylate and thymidylate synthase Biochemistry 26 1987 8606 8613
5. Grem JL Hoth D Hamilton MJ An overview of the current status and future directions of clinical trials of 5-fluorouracil and folinic acid Cancer Treat Rep 71 1987 1249 1264
6. Piedbois P Buyse M Rustum Y For the Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by, leucovorin in patients with advancel, colorectal cancer: Evidence in terms of response rate J Clin Oncol 10 1992 896
7. Kufe DW Major PP 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity J Biol Chem 256 1981 9802 9805
8. Glazer RI Lloyd LS Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture Mol Pharmacol 21 1982 468 473
9. Kanamaru R Kakuta H Sato T The inhbitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro Cancer Chemother Pharmacol 17 1986 43 46
10. Will CL Dolnick BJ 5-fluorouracil inhibits dihydrofolate reductase precursor mRNa processing and/or nuclear mRNA stability in methotrexate-resistant KB cells J Biol Chem 264 1989 21413 21421
11. Armstrong RD Lewis M Stern SG Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism J Biol Chem 261 1986 7366 7371
12. Takimoto CH Voeller DB Strong JM Effects of 5-fluorouracil substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA J Biol Chem 28 1993 21438 21442
13. Danenberg PV Shea LCC Danenberg K Effect of 5-fluorouracil substitution on the self-splicing activity of Tetrahymena ribosomal RNA Cancer Res 50 1990 1757 1763
14. Santi DV Hardy LW Catalytic mechanism and inhibition of tRNA (uracil-5)methyltransferase: Evidence for covalent catalysis Biochemistry 26 1987 8599 8606
15. Samuelsson T Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil Nucleic Acids Res 19 1991 6139 6144
16. Jin Y Heck DE DeGeorge G 5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells Cancer Res 56 1996 1978 1982
17. Doong SL Dolnick BJ 5-Fluorouracil substitution alters pre-mRNA splicing in vitro J Biol Chem 263 1988 4467 4473
18. Patton JR Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine Biochemistry 32 1993 8939 8944
19. Wu XP Dolnick BJ 5-Fluorouracil alters dihydrofolate, reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction Mol Pharmacol 44 1993 22 29
20. Lenz H-J Manno DJ Danenberg KD Incorporation of 5-fluorouracil into U2 and U6 snRNA inhibits mRNA precursor splicing J Biol Chem 269 1994 21962 31968
21. Grem JL Mulcahy RT Miller EM Interaction of deoxyuridine with fluorouracid and dipyridamole in a human colon cancer cell line Biochem Pharmacol 38 1989 51 59
22. Curtin NJ Harris AL Aherne GW Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxy-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole Cancer Res 51 1991 2346 2352
23. Aherne GW Hardcastle A Raunaud F Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition: Effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukemia cells Biochem Pharmacol 51 1996 1293 1301
24. Major PP Egan E Herrick D 5-Fluorouracil incorporation in DNA of human breast carcinoma cells Cancer Res 42 1982 3005 3009
25. Schuetz JD Wallace HJ Diasio RB 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity Cancer Res 44 1984 1358 1363
26. Canman CE Lawrence TS Shewach DS Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate Cancer Res 53 1993 5219 5224
27. Mauro DJ De Riel JK Tallarida RJ Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells Mol Pharmacol 43 1993 854 857
28. Houghton JA Tillman DM Harwood FG Ratio of 2′-doexyadenosine-5′-triphosphate/thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death Clin Cancer Res 1 1995 723 730
29. Yoshioka A Tanaka S Hiraoka O Deoxyribonucleoside triphosphate imbalance — fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death J Biol Chem 262 1987 8235 8241
30. Yin M Rustum YM Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: Relevance to cell growth inhibition Cancer Commun 3 1991 45 51
31. Jones S Willmore F Durkaca BW The effect of 5-fluoropyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral clution Carcinogenesis 15 1994 2435
32. Geoffroy FJ Allegra CJ Sinha B Enhanced cytotoxicity with interleuin-1α and 5-fluorouracil in HCT116 colon cancer cells Oncol Res 6 1994 581 591
33. Ayusawa D Arai H Wataya Y A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells Mutat Res 200 1988 221 230
34. Canman CE Tang H-Y Normolle DP Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanisms of resistance and cytotoxicity Proc Natl Acad Sci USA 89 1992 10474 10478
35. Li Z-R Yin M-B Arredendo MA Down-regulation of c-myc gene expression with induction of high molecular weight DNA fragments by fluorodeoxyuridine Biochem Pharmacol 48 1994 327 334
36. Houghton JA Morton CL Adkins DA Locus of the interaction among 5-fluorouracil, leucovorin, and interferonα2a in colon carcinoma cells Cancer Res 53 1993 4243 4250
37. Lowe SW Ruley HE Jacks T p53-Dependent apoptosis modulates the cytotoxicity of anticancèr agents Cell 74 1993 957 967
38. Fisher TC Milner AE Gregory CD Bcl-2 modulation, of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways Cancer Res 53 1993 3321 3326
39. Pickard M Dive C Kinsella AR Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis Br J Cancer 72 1995 1389 1396
40. Aschele C Sobrero A Faderan MA Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules Cancer Res 52 1992 1855 1864
41. Sobrero AF Aschele C Bertino JB Fluorouracil in colorectal cancer—a tale of two drugs: Implications for biochemical modulation J Clin Oncol 15 1997 368 381
42. Leichman L Lenz H-J Leichman CG Quantitation of intratumoral thymidylate synthase expression predicts for response to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial Eur J Cancer 31A 1995 1306 1309
43. Alexander HR Grem JL aiHamilton^JH Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma Cancer J Sci Am 1 1995 49 54
44. Lenz H-J Leichman CG Danenberg K Thymidylate synthase mRNA levels in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival J Clin Oncol 14 1996 176 182
45. Zalcberg J Cunningham D Van Cutsem E ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer J Clin Oncol 14 1996 716 721
46. Chu E Lai G-M Zinn S Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA Mol Pharmacol 38 1990 410 417
47. Radparvar S Houghton PJ Houghton JA Effect of polyglutamylation of 5,10-methylentetrahydrofolate on the binding of 5-fluoro-2-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft Biochem Pharmacol 38 1989 335 342
48. Wang F-S Aschele C Sobrero A Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance Cancer Res 53 1993 3677 3680
49. Barbour KW Berger SH Berger FG Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase Mol Pharmacol 37 1990 515 518
50. Berger SH Jenh C-H Johnson LF Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells Mol Pharmacol 28 1985 461 467
51. Chu E Drake JC Koeller DM Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines Mol Pharmacol 139 1991 136 143
52. Chu E Koeller DM Casey JL Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase Proc Natl Acad Sci USA 88 1991 8977 8981
53. Swain SM Lippman ME Chabner BA Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer J Clin Oncol 7 1989 890 899
54. Heggie GD Sommadossi J-P Cross DS Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 1987 2203 2206
55. Van Groenigen CJ Pinedo HM Heddes J Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule Cancer Res 48 1988 6956 6961
56. Grem JL McAtee N Steinberg S A pilot study of interferon alfa-2a in combination with 5-fluorouracil and plus high-dose leucovorin in metastatic gastrointestinal carcinoma J Clin Oncol 9 1991 1811 1820
57. Grem JL McAtee N Murphy RF Phase I and pharmacokinetic study of recombinant human granulocytemacrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma J Clin Oncol 12 1994 560 568
58. Lu Z Zhang R Diasio RB Purification and characterization of dihydropyrimidine dehydrogenase from human liver J Biol Chem 267 1992 17102 17109
59. Zhang R Soong S-J Liu T Pharmacokinetics and tissue distribution of 2-fluoro-β-alanine in rats: Potential relevance to toxicity pattern of 5-fluorouracil Drug Metal Dispos 20 1992 113 119
60. Diasio RB Beavers TL Carpenter T Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity J Clin Invest 81 1988 47 51
61. Lu A Zhang R Diasio RB Dihydropyrimidine, dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy Cancer Res 53 1993 5433 5438
62. Harris BE Song R Soong S-J Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion Cancer Res 50 1990 197 201
63. Grem JL McAtee N Balis F A Phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma Cancer 72 1993 663 668
64. Anderson LW Parker RJ Collins JM Gas chromatographic-mass, spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions J Chromatogr 581 1992 195 201
65. Yoshida T Araki E Iigo M Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer Cancer Chemother Pharmacol 26 1990 352 354
66. Thyss A Milano G Renee N Clinical pharmacokinetic study of 5-FU in continuous, 5-day infusions for head and neck cancer Cancer Chemother Pharmacol 16 1986 64 66
67. Santini J Milano G Thyss A 5-FU therapeutic monitoring with dose adjustment, leads to an improved therapeutic index in head and neck cancer Br J Cancer 59 1989 287 290
68. Erlichman C Fine S Elhakin T Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol Cancer Treat Rep 70 1986 903 904
69. Trump DL Egorin MJ Forrest A Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole J Clin Oncol 9 1991 2027 2035
70. Petit E Milano G Levi F Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients Cancer Res 48 1988 1976 1980
71. Remick SC Grem JL Fischer PH Phase I trial of 5-fluorouracil and dipyridamole administered by 72-hour concurrent continuous infusions Cancer Res 50 1990 2667 2672
72. Grem JL McAtee N Steinberg SM A Phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N -(phosphonacetyl)- l -aspartate in metastatic gastrointestinal adenocarcinoma Cancer Res 53 1993 4828 4836
73. Hageboutrous A Rogatko A Newman EM Phase I study of phosphonacetyl- l -aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer Cancer Chemother Pharmacol 35 1995 205 212
74. Marsh JC Bertino JR Katz KH The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer J Clin Oncol 9 1991 371 380
75. Piedbois P Buyse M Blijham G Advanced Colorectal Cancer Meta-Analysis Project Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer J Clin Oncol 12 1994 960 969
76. O'Connell MJ Martenson JA Wieand HS Improving adjuvant, therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery N Engl J Med 331 1994 502 507
77. Leichman CG Fleming TR Muggia FM Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study J Clin Oncol 131 1995 1303 1312
78. Seifert P Baker L Reed ML Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma Cancer 36 1975 123 128
79. Lokich JJ Ahlgren JD Gullo JJ A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study J Clin Oncol 7 1989 425 432
80. Fuji S Ikenaka K Fukushima M Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil Jpn J Cancer Res 69 1979 763 772
81. Ho DH Cobington WP Pazdur R Clinical pharmacology of combined oral uracil and ftorafur Drug Metab Disp 20 1992 936 940
82. Muggia FM Wu X Spicer DM Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil Clin Cancer Res 2 1996 1461 1467
83. Ota K Taguchi T Kimura K Report on nationwide pooled data and cohort investigation, in UFT phase II study Cancer Chemother Pharmacol 22 1988 333 338
84. Saltz LB Leichman CT Young CW A fixed ratio combination of uracil and ftorafur (UFT) with low dose leucovorin Cancer (Phila) 75 1995 782 785
85. Pazdur R Lassere Y Rhodes V Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma J Clin Oncol 12 1994 2296 2300
86. Shirasaka T Nakano K Takechi T Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypridine-1 M, potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 1996 2602 2606
87. (abstr 466) Horikoshi N Mitachi Y Sakata Y S-1 new oral fluoropyprimidine is very active in patients with advanced gastric cancer Proc Am Soc Clin Oncol 15 1996 206
88. (abst 223) Taguchi T Shirasaka T New oral anticancer agent: S-1 Annals Oncol 7 suppl 1 1996 66
89. (abstr 151) Taguchi T Horikoshi N Kinoshita H Early Phase II study of S-1 in patients with advanced breast cancer Proc Am Soc Clin Oncol 15 1996 121
90. Spector T Harrington JA Porter DJT 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo Biochem Pharmacol 46 1993 2243
91. Baccanari DP Davis ST Knick V 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil Proc Natl Acad Sci USA 90 1993 11064 11068
92. Cao S Rustum YM Spector T 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma Cancer Res 54 1994 1507 1510
93. Spector T Cao S Rustum YM Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dyhydrouracil Cancer Res 55 1995 1239 1241
94. Baker SD Khor SP Adjei AA Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase J Clin Oncol 14 1996 3085 3096
95. el Khouni MH el Kouni MM Naguib NM Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases Implications for chemotherapy with 5-fluoropyrimidines Cancer Res 53 1993 3687 3693
96. Kono A Hara Y Sugata S Activation of 5′-deoxyfluorouridine by thymidine phosphorylase in human tumors Chem Pharm Bull 31 1983 175 178
97. Armstrong RD Cadman E 5′-deoxyfluorouridine selective toxicity for human tumor cells compared to human bone marrow Cancer Res 43 1983 2525 2528
98. Bajetta E Colleoni M Di Bartolomeo M Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer J Clin Oncol 13 1995 2613 2619
99. (abstr 1509) Twelves C Budman DR Creaven PJ Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies Proc Am Soc Clin Oncol 15 1996 476
100. (abst 297) Hughes M Planting A Twelves C A Phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer Ann Oncol 7 suppl 1 1996 87